Hemostatic activation and inflammatory response during cardiopulmonary bypass: Impact of heparin management

Anesthesiology

Volumn 97, Issue 4, 2002, Pages 837-841

  Koster, Andreas ^a,c   Fischer, Thomas ^a   Praus, Michael ^b   Haberzettl, Helmut ^a   Kuebler, Wolfgang M ^a   Hetzer, Roland ^a   Kuppe, Herman ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN III; APROTININ; BETA THROMBOGLOBULIN; D DIMER; FIBRIN; HEPARIN; LEUKOCYTE ELASTASE; MIDAZOLAM; PADGEM PROTEIN; PANCURONIUM BROMIDE; PROPOFOL; SUFENTANIL;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BIOMETRY; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HEPARINIZATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0036790231     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200210000-00014     Document Type: Article

References (22)

1. Despotis G, Avidan MS, Hogue CW: Mechanisms of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001; 72:1821-31
2. Mojcik C, Levy JH: Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg 2001; 71:745-54
3. Spiess B: Blood transfusion: The silent epidemic. Ann Thorac Surg 2001; 72:1832-7
4. Leal-Noval RS, Rincon-Ferrari MD, Garcia-Curiel A, Herruzo-Aviles A, Camacho-Larana P, Garncho-Montero J, Amaya-Villar R: Transfusions of blood components and postoperative infection in patients undergoing cardiac surgery. Chest 2001; 119:1641-68
5. Iandis CR, Dorian OH, Taylor KM: New anti-inflammatory and platelet preserving effects of aprotinin. Ann Thorac Surg 2001; 72:1808-13
6. Levy JH: Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg 2001; 72:1814-20
7. Brosstad OE, Am Hollen E, Abdelnoor M: Effects of coagulation and fibrinolysis with reduced versus full heparinization and heparin-coated cardiopulmonary bypass. Circulation 1995; 92:2579-84
8. Despotis GJ, Gravlee G, Filos K, Levy J: Anticoagulation monitoring during cardiac surgery. Anesthesiology 1999; 91:1122-115
9. Despotis GJ, Joist JH: Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: An update. J Cardiothorac Vasc Anesth 1999; 13:18-29
10. Shigeta O, Kojima H, Hiramatsu Y, Jikuya T, Terada Y, Atsumi N, Sakakibara Y, Nagasawa T, Mitsui T: Low dose protarnine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 118:354-60
11. Despotis GJ, Joist JH, Hogue CW Jr, Alsoufiev A, Kater K, Goodnough LT, Santoro SA, Spitznagel E, Rosenblum M, Lappas DG: The impact of heparin concentration and activated clotting time monitoring on blood conservation: A prospective randomized evaluation in patients undergoing cardiac operation. J Thorac Caediovasc Surg 1996; 111:493-54
12. Hardy JF, Belisle S, Robitaille D, Perrault J, Roy M, Gagnon L: Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg 1996; 112:154-61
13. Despotis GJ, Joist JH, Goodnough LT, Santoro SA, Spitznagel E: Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements. J Thorac Cardiovasc Surg 1997; 113:611-3
14. LaDuca FM, Zucker ML, Walker CE: Assessing heparin neutrlization following cardiac surgery: Sensitivity of thrombin time based assays versus ptotamine titration methods. Perfusion 1999; 14:181-7
15. Codspoti M, Ludlam CA, Simpson D, Mankad PS: Individualized heparin and protamine management in infants and children undergoing cardiac operations. Ann Thorac Surg 2001: 71:922-7
16. Despotis GJ, Joist HJ, Hogue CW Jr, Alsoufiev A, Joiner-Maier D, Santoro SA, Spitznagel E, Weitz JI, Goodnough LT: More effective suppression of hemostatic system activation in patients undergoing surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76:902-8
17. Koster A, Kukucka M, Kuppe H: Postoperative blood loss and re-exploration following CPB: Heparin management with protamine titration assay versus an ACT regimen (abstract). Anesthesiology 2000; 92(suppl 1):A-409
18. Jeske W, Lormeau JC, Callas, Iqbal O, Hoppensteadt D, Farred J: Anti-thrombin III affinity dependence on the anticoagulant, antiprotemase, and tissue factor pathway inhibitor actions of heparins. Semin Thromb Hemost 1995; 21:193-200
19. Weber C, Springer TA: Neutrophil accumulation on activated surface-adherent platelets in flow is mediated by interaction of mac-1 with fibrinogen bound to αIIbβ3 and stimulated by platelet activating factor. J Clin Invest 1997; 100:2085-93
20. Li N, Hu H, Linqvist M, Wikstrom-Jonsson E, Goodall AH, Hjemdahl P: Platelet leucocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20:2702-8
21. Neumann FJ, Marx N, Gawaz. Brand K, Ott I, Rokitta C, Sticherling C, Meinl C, May A, Schomig A: Induction of cytokine expression in leukocytes by binding of thrombin stimulated platelets. Circulation 1997; 95:2387-94
22. Woodman RC, Ostrovsky L, Teoh D, Payne D, Poon MC, Kubes P: Anti-thrombin and ischemia/reperfusion. Blood Coagul Fibrinolysis 1998; 9(suppl 2):7-15